Vanda Pharmaceuticals Inc. Expected to Post Q3 2017 Earnings of ($0.13) Per Share (VNDA)
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Analysts at Jefferies Group issued their Q3 2017 earnings per share estimates for Vanda Pharmaceuticals in a research report issued to clients and investors on Thursday. Jefferies Group analyst M. Andrews expects that the biopharmaceutical company will earn ($0.13) per share for the quarter. Jefferies Group currently has a “Buy” rating and a $21.00 target price on the stock. Jefferies Group also issued estimates for Vanda Pharmaceuticals’ Q4 2017 earnings at ($0.18) EPS, FY2017 earnings at ($0.51) EPS, FY2018 earnings at ($0.32) EPS, FY2019 earnings at $1.38 EPS, FY2020 earnings at $1.30 EPS and FY2021 earnings at $1.71 EPS.
Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative return on equity of 7.88% and a negative net margin of 6.54%. The business had revenue of $42.06 million for the quarter, compared to analyst estimates of $40.31 million. During the same period last year, the company earned $0.01 EPS. Vanda Pharmaceuticals’s revenue for the quarter was up 16.7% compared to the same quarter last year.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/08/09/vanda-pharmaceuticals-inc-expected-to-post-q3-2017-earnings-of-0-13-per-share-vnda.html.
A number of other research analysts have also recently commented on the company. Piper Jaffray Companies set a $23.00 target price on Vanda Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 3rd. HC Wainwright set a $18.00 target price on Vanda Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 3rd. Oppenheimer Holdings, Inc. set a $21.00 price objective on Vanda Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 3rd. TheStreet raised Vanda Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Friday, May 12th. Finally, Zacks Investment Research raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, June 14th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $21.33.
Vanda Pharmaceuticals (NASDAQ:VNDA) opened at 15.50 on Monday. The company’s 50-day moving average price is $16.07 and its 200 day moving average price is $14.63. Vanda Pharmaceuticals has a 52-week low of $11.58 and a 52-week high of $18.00. The company’s market capitalization is $693.13 million.
Several hedge funds have recently modified their holdings of VNDA. Legal & General Group Plc raised its stake in shares of Vanda Pharmaceuticals by 37.4% in the second quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock valued at $181,000 after buying an additional 3,022 shares in the last quarter. Virginia Retirement Systems ET AL purchased a new position in shares of Vanda Pharmaceuticals during the first quarter worth about $193,000. Capital Fund Management S.A. purchased a new position in shares of Vanda Pharmaceuticals during the first quarter worth about $195,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Vanda Pharmaceuticals during the first quarter worth about $196,000. Finally, AQR Capital Management LLC purchased a new position in shares of Vanda Pharmaceuticals during the fourth quarter worth about $223,000. Hedge funds and other institutional investors own 91.42% of the company’s stock.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.